Skip to main content

Table 4 Percentage of responders in the clinical evaluation of cefditoren efficacy in clinical trials. Published data

From: Revisiting cefditoren for the treatment of community-acquired infections caused by human-adapted respiratory pathogens in adults

  References Cefditoren 200 mg bid Cefditoren 400 mg bid Comparatorsa
EOTb EFc EOTb EFc EOTb EFc
Pharyngotonsillitis 90-92 93.4 – 98.6 88.9–99.2 88.6–97.1 84.4–100
Rhinosinusitis 90,93 81.3–95.2 63.6–91.0 76.5–83.1 70.2–71.9 75.5–97.7 66.2–95.1
AECBd 89,94–97 80–88.8 79.7–83.0 84.4–95.5 78.1–85.6 75.0–98.9 79.8–85.7
CAPe 89,98,99 87.2 – 91.8 88.4–87.8 89.2–90.1 83.7–87.2 90.3–92.2 87.8–93.8
  1. aPenicillin V or VK (90–92) for pharyngotonsillitis, amoxicillin/clavulanic acid (90,93) or cefuroxime (90) for rhinosinusitis, cefuroxime (89,94,96) or clarithromycin (89,95) for AECB, and amoxicillin/clavulanic acid (89,98), and cefpodoxime (89,99) for CAP
  2. bEOT = End of Treatment
  3. cEF = End of Follow up
  4. dAECB = Acute exacerbation of chronic bronchitis
  5. eCAP = Community-acquired pneumonia